 |
인쇄하기
취소
|
Daewoong enters agreement with Medivir for MIV-210, hepatitis B and HIV therapy
Daewoong Pharm announced on March 22 that it has signed an exclusive license and supply agreement with Medivir AB, a Sweden based pharmaceutical company, for a novel hepatitis B virus (HBV) polymerase inhibitor drug, lagociclovir valactate (MIV-210).
Under the terms of the agreement, Daewoong will assume responsibility for clinical development and have marketing rights in Korea, Japan and Ch...
Under the terms of the agreement, Daewoong will assume responsibility for clinical development and have marketing rights in Korea, Japan and Ch...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.